Related by context. All words. (Click for frequent words.) 82 metastatic castration resistant 80 metastatic androgen independent 76 metastatic hormone refractory 74 castrate resistant prostate cancer 73 hormone refractory metastatic prostate 72 refractory chronic lymphocytic 72 resistant hormone refractory 72 HER2 positive metastatic breast 72 metastatic pancreatic 71 prostate cancer CRPC 71 Hormone Refractory Prostate Cancer 71 recurrent metastatic 70 FOLOTYN ® 70 dasatinib Sprycel ® 70 metastatic colorectal 70 oral ridaforolimus 70 sorafenib tablets 70 advanced metastatic prostate 70 erlotinib Tarceva ® 70 gemcitabine chemotherapy 70 5 fluorouracil leucovorin 70 unresectable stage 70 recurrent NSCLC 69 BRIM2 69 alvespimycin 69 evaluating picoplatin 69 AVASTIN 69 Cloretazine ® 69 Pivotal Phase III 69 metastatic CRPC 69 stage IIIb IV 69 prostate cancer HRPC 69 Aflibercept 69 FOLFOX6 69 Initiate Phase 69 metastatic renal cell 69 lintuzumab SGN 68 MAGE A3 ASCI 68 unresectable locally advanced 68 cetuximab Erbitux 68 Combination REOLYSIN R 68 bevacizumab Avastin ® 68 Adjuvant Treatment 68 metastatic renal cell carcinoma 68 Peginterferon alfa 2b 68 Trial Evaluating 68 Phase #b/#a clinical 68 Folfox 68 Randomized Phase 68 phase IIb clinical 68 plus dacarbazine 68 VEGFR2 inhibitor 68 oral nucleoside analogue 68 interferon gamma 1b 68 cetuximab Erbitux ® 68 Patients Treated With 68 deCODE ProstateCancer TM 68 Epothilone D 68 dependent kinase inhibitor 68 recurrent glioblastoma multiforme 68 stage IIIB 68 ELACYT 68 Xeloda ® 67 Ixempra 67 Meets Primary Endpoint 67 Amrubicin 67 refractory metastatic 67 metastatic gastric 67 advanced metastatic renal 67 Pivotal Phase 67 evaluating T DM1 67 relapsed leukemia 67 ThermoDox R 67 Personalized Immunotherapy 67 Vicinium TM 67 refractory cutaneous T 67 Cloretazine 67 prostate cancer mCRPC 67 luteinizing hormone releasing 67 hyperplasia BPH 67 Completes Patient Enrollment 67 Cutaneous T 67 Relapsed Refractory 67 Nexavar sorafenib 67 cell lymphoma CTCL 67 relapsed refractory multiple myeloma 67 assessing T DM1 67 relapsed MM 67 trastuzumab Herceptin R 67 chemotherapy cisplatin 67 BR.# 67 LHRH receptor positive 67 PEGylated Fab fragment 67 autologous cellular immunotherapy 67 tumors GIST 67 radiation sensitizer 67 evaluating tivozanib 67 R roscovitine CDK cyclin 67 virus HCV protease inhibitor 67 sunitinib malate 67 Annamycin 67 metastatic colorectal carcinoma 67 Neoadjuvant 67 IgG1 monoclonal antibody 67 capecitabine Xeloda 66 Camptosar ® 66 essential thrombocythemia ET 66 antibody MAb 66 irinotecan doxorubicin oxaliplatin paclitaxel 66 bortezomib Velcade R 66 Randomized Phase II 66 Brentuximab Vedotin SGN 66 Phase 2b Clinical Trial 66 castration resistant hormone refractory 66 irinotecan containing 66 plus prednisone 66 infusional 5-FU/LV 66 gastrointestinal stromal tumors GIST 66 pegylated interferon alfa 2a 66 docetaxel Taxotere R 66 CYT# potent vascular disrupting 66 refractory indolent non 66 PROVENGE ® 66 opioid induced constipation OIC 66 androgen independent 66 cutaneous T cell 66 lexidronam injection 66 PNP inhibitor 66 Prednisone Against Refractory 66 systemic anaplastic large 66 Study Evaluating 66 5 FU leucovorin 66 PI3K/Akt pathway inhibitor 66 advanced unresectable 66 PANVAC VF 66 bevacizumab Avastin 66 Albuferon TM 66 investigational antiplatelet agent 66 Temsirolimus 66 LHRH antagonist 66 Intravenous CP 66 oropharyngeal candidiasis OPC 66 BRIM3 66 metastatic HRPC 66 Ceflatonin 66 cutaneous T 66 dasatinib Sprycel 66 FOLFOX6 chemotherapy regimen 66 Daclizumab 66 sorafenib Nexavar 66 alfa 2a 66 generation purine nucleoside 66 Dendreon investigational 66 induced macular edema 66 Phase IIb Trial 66 minimally symptomatic metastatic castrate 66 Advanced Renal Cell 66 Romidepsin 66 hormone refractory prostate cancer 66 biliary tract cancer 66 undergoing androgen deprivation 66 intravesical infusion therapy 66 IL# PE#QQR 66 gemcitabine Gemzar ® 66 OvaRex ® MAb 66 Clevudine 66 Temodar ® 66 omacetaxine mepesuccinate 66 non resectable metastatic 66 cancer mCRC 66 Irinotecan 66 FEMALES SHOULD BE ADVISED 66 Advanced Melanoma 66 Soft Tissue Sarcoma 66 metastatic HER2 negative 66 estramustine 65 cell carcinoma RCC 65 trastuzumab DM1 65 forodesine 65 Phase Ib II 65 mRCC 65 myelodysplastic myeloproliferative diseases 65 ongoing Phase 1b 65 Achieves Primary Endpoint 65 Proxinium TM 65 SUPPRELIN R LA 65 fallopian tube carcinoma 65 non nucleoside inhibitor 65 Metastatic Prostate Cancer 65 brain metastases originating 65 AAG geldanamycin analog 65 non squamous 65 cetuximab Erbitux R 65 refractory multiple myeloma 65 mapatumumab 65 novel VDA molecule 65 anthracycline taxane 65 lymphoid malignancies 65 metastatic malignant 65 Phase III randomized controlled 65 Avastin bevacizumab 65 castration resistant prostate cancer 65 MEK Inhibitor 65 Bevacizumab 65 pralatrexate injection folate analogue 65 pan histone deacetylase 65 MKC# MT 65 chemosensitizer 65 Novel Oral 65 Xelox 65 refractory metastatic colorectal cancer 65 YONDELIS R 65 novel nucleoside analog 65 Tarceva TM 65 recurrent metastatic ovarian cancer 65 thymalfasin 65 Hsp# Inhibitor 65 Prostate AdenoCarcinoma Treatment 65 orally administered inhibitor 65 TAXOTERE R 65 Acute Myeloid Leukemia AML 65 Genasense ® 65 paclitaxel carboplatin 65 Allovectin 7 65 Phase IIIb clinical 65 acyclovir Lauriad R 65 YONDELIS 65 Iluvien TM 65 mCRC patients 65 modified glutathione analog 65 Fast Track Status 65 CDK cyclin dependent 65 metastatic GIST 65 multicenter Phase III 65 BRAF mutant 65 TO AVOID PREGNANCY WHILE 65 imatinib Gleevec ® 65 ZACTIMA 65 Phase III Clinical Trial 65 Herceptin trastuzumab 65 ixabepilone 65 Panzem NCD 65 Phase Ib clinical trials 65 EGFR expressing metastatic colorectal 65 Lenalidomide 65 IMA# 65 registrational Phase 65 plus gemcitabine 65 GW# [003] 65 leukemia AML 65 trastuzumab DM1 T DM1 65 nilotinib Tasigna ® 65 unresectable Stage III 65 delivers fluocinolone acetonide FA 65 non squamous NSCLC 65 Renal Cell Carcinoma 65 Taxotere docetaxel 65 Elagolix 65 TKB# 65 Completes Enrollment 65 receptor tyrosine kinase inhibitor 65 refractory colorectal cancer 65 phase III isavuconazole 65 LymphoStat B belimumab 64 randomized controlled Phase 64 paclitaxel Taxol R 64 investigational immunotherapy 64 HGS ETR2 64 asymptomatic metastatic 64 Initiates Phase III 64 Tanespimycin 64 Panzem R NCD 64 docetaxel Taxotere ® 64 paclitaxel Taxol ® 64 ospemifene 64 R lenalidomide 64 Metastatic Melanoma 64 Panzem R 64 Navelbine ® 64 HRPC 64 elacytarabine 64 Bayer Nexavar 64 telaprevir dosed 64 nonmetastatic 64 cisplatin gemcitabine 64 Pemetrexed 64 Femara letrozole 64 Bayer HealthCare Onyx Pharmaceuticals 64 liposomal formulation 64 Metastatic Colorectal Cancer 64 Campath alemtuzumab 64 Degarelix 64 mTOR inhibitor 64 tanespimycin 64 Vitrasert R 64 galiximab 64 Medullary Thyroid Cancer 64 TNF Tumor Necrosis Factor 64 REVIVE Diabetes 64 immunotherapeutic agent 64 resistant ovarian cancer 64 nucleoside analog 64 aflibercept VEGF Trap 64 Sapacitabine 64 PROVENGE sipuleucel T 64 indolent follicular non 64 Phase Ib IIa 64 SinuNase TM 64 HBeAg negative 64 Gemcitabine 64 Oral Fingolimod 64 histone deacetylase HDAC inhibitor 64 Phase 2b Study 64 R sorafenib tablets 64 Melphalan 64 HGS ETR1 64 oral chemotherapeutic agent 64 ACTEMRA TM 64 symptomatic BPH 64 refractory acute myeloid 64 Aplidin 64 unresectable recurrent 64 HDAC Inhibitor 64 pertuzumab 64 custirsen 64 TBC# 64 catheter occlusion 64 Azacitidine 64 RCW Breast Cancer 64 relapsed multiple myeloma 64 Voreloxin 64 FUSILEV enhances 64 GVAX Immunotherapy 64 MyVax R 64 EGFR expressing mCRC 64 PrevOnco 64 Nexavar ® 64 Initiates Enrollment 64 severe hypercholesterolemia 64 R Saizen R 64 vinca alkaloid 64 Paraplatin ® 64 Vascular Disrupting Agent 64 thetreatment 64 octreotide implant 64 relapsed ovarian cancer 64 dacarbazine DTIC 64 ORENCIA ® 64 RANK Ligand inhibitor 64 Pivotal Trial 64 Dose Ranging Study 64 oral deforolimus 64 PSMA ADC 64 Xeloda capecitabine 64 abiraterone acetate 64 metastatic bladder 64 Syncria R 64 Initiates Phase II 64 standard chemotherapy regimen 64 hematological cancers notably 64 dacarbazine 64 metaglidasen 64 RhuDex R 64 Complicated Skin 64 telomerase therapeutic 64 overactive bladder VANTAS R 64 chronic myeloid 64 Safinamide 64 Phase III Pivotal 64 sarcoma melanoma 64 Pralatrexate 64 Jevtana 64 hormone LHRH antagonist 64 pegylated liposomal doxorubicin 64 Thiarabine 64 Fludara ® 64 Tezampanel 64 Taxotere ® 64 Vidaza ® 64 unresectable tumors 64 BENLYSTA ® 64 anticancer compound 64 Kit CD# positive 64 INSPIRE Trial Phase III 64 EFAPROXYN 64 Ozarelix 64 sorafenib Nexavar ® 64 bevacizumab Avastin R 64 Genasense ® oblimersen 64 LENALIDOMIDE 64 Phase #/#a trial 64 PDX pralatrexate 64 gastrointestinal stromal tumors 63 ocular formulation 63 BCG refractory carcinoma 63 toenail onychomycosis 63 Prolongs Survival 63 metastatic CRC 63 Pirfenidone 63 relapsing remitting MS RRMS 63 goserelin 63 Pooled Analysis 63 clinical trials Archexin 63 Malignant Melanoma 63 Clinical Trial Evaluating 63 interferon alfa 2a 63 Androgen Deprivation Therapy 63 sunitinib Sutent 63 generation PNP inhibitor 63 lenalidomide Revlimid R 63 following fluoropyrimidine oxaliplatin 63 dose escalation clinical 63 ritonavir boosted 63 Genasense oblimersen sodium Injection 63 RhuDex ® 63 vinorelbine tartrate 63 investigational oral inhibitor 63 advanced HER2 positive 63 systemic RNAi therapeutic 63 sunitinib Sutent ® 63 Provenge sipuleucel T 63 mertansine 63 IMiDs ® 63 rALLy 63 Receives Orphan Drug Designation 63 unresectable 63 HGS ETR1 mapatumumab 63 unique alkylating agent 63 SPRYCEL ® 63 stage IIIB IV 63 phase IIb study 63 Naive Patients 63 Vidaza R 63 mitoxantrone plus 63 novel tubulin binding 63 Aplidin R 63 pain palliation 63 Pharmacokinetics PK 63 Silodosin 63 Initiates Clinical Trial 63 oral prodrug 63 Vicriviroc 63 Previously Treated 63 adecatumumab MT# 63 Letairis ambrisentan 63 bone marrow reticulin deposition 63 bladder ovarian 63 3 registrational trial 63 cetrorelix pamoate 63 Frozen Shoulder syndrome Adhesive 63 BLP# Liposome Vaccine 63 clinically localized prostate 63 minimally symptomatic 63 evaluating Prochymal 63 Glufosfamide 63 PHASE III 63 Sprycel dasatinib 63 Phase Ib clinical 63 CD3 monoclonal antibody 63 Abiraterone acetate 63 humanised monoclonal antibody 63 evaluating satraplatin 63 PrevOnco ™ 63 Capecitabine 63 BRAF inhibitor 63 Refractory Hodgkin Lymphoma 63 previously untreated follicular 63 Urocidin 63 CR# vcMMAE 63 Patient Enrollment 63 Peginterferon 63 pan HDAC inhibitor 63 XYOTAX TM 63 vidofludimus 63 Prospective Randomized 63 gastrointestinal stromal tumor GIST 63 FDA APPROVES 63 Metabolic Efficiency 63 Bosutinib 63 Zorbtive TM 63 non splenectomized 63 Cloretazine R VNP#M 63 VELCADE melphalan 63 PEGylated anti 63 Vidaza azacitidine 63 methylnaltrexone bromide 63 Granted Orphan Drug 63 Severe Sepsis 63 XL# anticancer compounds 63 including eniluracil ADH 63 paclitaxel poliglumex 63 melphalan prednisone 63 comparator arm 63 plus dexamethasone 63 adecatumumab 63 Zytiga 63 hepatocellular cancer 63 PF # [002] 63 Vandetanib 63 PROSTVAC TM 63 OMP #R# 63 Drug Candidate 63 CTAP# Capsules 63 PEGINTRON TM 63 ® lenalidomide 63 LymphoStat B TM 63 Randomized Double blind 63 candidates Azedra TM 63 Evoltra ® 63 Anturol TM 63 metastatic ocular 63 TASQ 63 Bezielle 63 tenofovir emtricitabine 63 trabectedin 63 novel emulsion formulation 63 Node Positive 63 Tykerb lapatinib 63 Advaxis Phase 63 nasal calcitonin product 63 Opterone R 63 occlusion PAO 63 topically applied SEPA 63 Xyfid TM 63 2 methoxyestradiol 63 antibody MT# 63 ovarian breast 63 Oral Calcitonin 63 gastrointestinal stromal 63 5-FU/LV 63 By JENNIFER LEARN 63 benign prostatic hyperplasia enlarged 63 APEX PD 63 Investigational Treatment 63 protease inhibitor PI 63 paclitaxel Taxol 63 EGFR TKI 63 Gemzar ® 63 II Clinical Trial 63 PROSTVAC VF 63 neratinib 63 lymphoma CTCL 63 GVAX R 63 Dose Escalation 63 testosterone buccal system 63 Hedgehog Pathway Inhibitor 63 Diabetic Macular Edema DME 63 Surgical resection 63 Neuvenge 63 temsirolimus 63 monoclonal antibody conjugated 63 VNP#M 63 Phase 2a Clinical Trial 63 Lucanix R 63 Previously Untreated 63 cyclophosphamide chemotherapy 63 androgen receptor antagonist 63 metastatic HER2 positive 63 Radiation Therapy SIRT 63 gemcitabine Gemzar 63 XELOX 63 oral picoplatin 62 Velcade bortezomib 62 Phase 1b clinical trials 62 iobenguane 62 miconazole Lauriad ® 62 low dose cytarabine 62 Onalta ™ 62 Stage IIIb 62 Newly Diagnosed Multiple Myeloma 62 approved incretin mimetic 62 glufosfamide 62 Proellex TM 62 demonstrated antitumor activity 62 Erbitux cetuximab 62 sapacitabine CYC# 62 Epratuzumab 62 oxaliplatin Eloxatin 62 CCX# B 62 Hycamtin 62 DCVax ® Brain 62 malignant ascites 62 NU# direct 62 registrational trial 62 Dementia Related Psychosis 62 RSR# 62 Phase III Trial 62 docetaxel Taxotere 62 Initiate Clinical Trial 62 squamous non 62 Testosterone MDTS R 62 BCIRG 62 pediatric acute lymphoblastic 62 metastatic carcinoma 62 GARDASIL ® 62 metastatic renal 62 Solazed 62 Luramist TM 62 talactoferrin 62 ZYBRESTAT 62 LSE ASM 62 hepatitis C HCV 62 remission induction 62 Lenocta TM 62 anthracycline containing 62 Solazed TM 62 docetaxel chemotherapy 62 Phase 2b clinical 62 Troxatyl 62 radiation chemoradiation 62 Investigational Oral 62 Clinical Trial Results 62 inhibitor RG# 62 Stage IIB 62 Onrigin 62 Presents Preclinical 62 Selective Internal 62 Tocilizumab 62 GVAX immunotherapy 62 systemic ALCL 62 AVOREN 62 IN PATIENTS WITH 62 Taxotere R 62 Gleevec imatinib mesylate 62 vincristine doxorubicin 62 cisplatin vinorelbine 62 NEBIDO R 62 pegylated interferon alpha 62 Ophena TM 62 R sipuleucel T 62 Bremelanotide 62 FUSILEV ® 62 carboplatin paclitaxel 62 Archexin 62 Chronic Myeloid Leukemia 62 RhuDex TM 62 TELINTRA R 62 phase IIb 62 Trastuzumab DM1 62 targeted radiotherapeutic 62 Antitumor Activity 62 primary hypercholesterolemia 62 relapsing multiple sclerosis 62 Initiates Phase 2b 62 Advanced Prostate Cancer 62 EGFr expressing metastatic colorectal 62 Alocrest 62 Orphan Drug status 62 IMC #B 62 adjuvant radiation 62 MKC# MKC# PP 62 EOquin TM 62 Matrix Phase 2b 62 oncolytic virus therapies 62 Capesaris 62 IMiDs ® compound 62 FOLFOX4 62 receiving chemoradiation therapy 62 LUX Lung 62 Edurant 62 Crofelemer budesonide foam 62 Roche Herceptin 62 Orally administered 62 Initiates Phase 62 Chronic Hepatitis C 62 IMPACT IMmunotherapy 62 Clolar ® 62 Randomized Double Blind 62 pharmacokinetic PK study 62 phase IIa clinical 62 ANCHOR trial 62 Quinamed 62 ErbB2 positive 62 ALVESCO R 62 Torisel temsirolimus 62 BCG refractory 62 refractory APL 62 Erlotinib 62 Apaziquone 62 ALN PCS 62 neuropathy sparing 62 adalimumab Humira 62 Xcellerated T Cells 62 familial amyloidotic polyneuropathy FAP 62 ZOLINZA 62 taxane resistant 62 Zolinza 62 unresectable liver cancer 62 Bazedoxifene 62 ADVEXIN p# therapy 62 Fludarabine 62 leukemia multiple myeloma 62 acetonide FA 62 Lenocta 62 Genasense R 62 volociximab 62 Pegasys ® 62 anti PlGF 62 chemoradiation therapy 62 INCB# [001] 62 XL# SAR# 62 Familial Adenomatous Polyposis FAP 62 Empatic TM 62 FDA Accepts 62 KRN# 62 OMAPRO ™ 62 humanized interleukin 6 62 TTF Therapy 62 trastuzumab Herceptin ® 62 Hepatocellular Carcinoma 62 vinorelbine 62 Cetrorelix 62 multiple myeloma MM 62 FOLFIRI 62 Peginterferon Alfa 2a 62 eribulin mesylate 62 Telik logo TELINTRA 62 interferon beta 1a infertility 62 Second Pivotal Phase 62 undergone radical prostatectomy 62 situ CIS 62 phase IIb trial 62 Pafuramidine 62 dextromethorphan quinidine 62 LibiGel ® 62 Cerebril TM 62 accumulate preferentially 62 axitinib 62 5 Fluorouracil 62 gemcitabine carboplatin 62 subcutaneous formulation 62 Adjuvant chemotherapy 62 Vectibix panitumumab 62 Monotherapy 62 lapatinib Tykerb 62 worsening thrombocytopenia 62 initiated Phase Ib 62 8mg/kg 62 DU #b 62 Phase 2b Trial 62 Fulvestrant 62 chronic eosinophilic leukemia 62 fosbretabulin 62 gefitinib Iressa 62 folinic acid FA 62 refractory prostate cancer 62 EOquin 62 generation Hsp# inhibitor 62 Phase IIb Clinical Trial 62 TLK# 62 Relapsed Multiple Myeloma 62 Ovitrelle R Serostim 62 antiretroviral naïve 62 nucleotide analogue 62 multi kinase inhibitor 62 Onalta TM 62 ACAPODENE TM 62 5 FU capecitabine 62 nonsmall cell lung cancer 62 KRAS wild 62 prostate cancer AIPC 62 Philadelphia Chromosome Positive 62 IIb clinical trial 62 CEQ# 62 phase IIa 62 Glaxo Tykerb 61 placebo controlled Phase III 61 Hycamtin ® 61 myelofibrosis MF 61 Luteinizing Hormone Releasing Hormone 61 Junovan TM 61 APPRAISE 61 keloid scarring 61 Trastuzumab 61 Nexavar tablets 61 investigational oral hepatitis C 61 paclitaxel cisplatin 61 novel histone deacetylase 61 Pivotal Study 61 developing Bicifadine serotonin 61 complement inhibitor eculizumab 61 phase Ib 61 investigational monoclonal antibody 61 brand ciclesonide HFA 61 polycythemia vera essential thrombocythemia 61 IV melanoma 61 CCR5 antagonist 61 Insegia 61 NMIBC 61 L BLP# 61 nab paclitaxel 61 MOZOBIL 61 vemurafenib 61 stage IIIb 61 PD LID 61 chemotherapy FOLFOX 61 Elotuzumab 61 ANYARA 61 NPC 1C 61 Blinatumomab 61 Mitoxantrone 61 Torisel 61 GATTEX ® 61 Pivotal Phase II 61 Recurrent Glioblastoma 61 external beam radiotherapy 61 treat male hypogonadism 61 colorectal lung 61 recurrent GBM 61 beta 1a 61 BCR ABL inhibitor 61 ELOXATIN 61 Bortezomib 61 OvaRex R 61 investigational hepatitis C 61 ASCO GI 61 Tesetaxel 61 Novartis Afinitor 61 delay bone metastases 61 FOLFIRI chemotherapy 61 Solazed ™ 61 huC# DM4 61 Begins Dosing 61 Renal Cell Carcinoma RCC 61 Mg Usa 61 Omnitarg 61 doublet chemotherapy 61 CINTREDEKIN BESUDOTOX 61 IMiDs R 61 potent CYP#A# inhibitors 61 JAK2 Inhibitor 61 PEGylated interferon beta 1a 61 AVE# 61 Diabetic Macular Edema 61 non metastatic osteosarcoma 61 carcinoma mCRC 61 PROSTATE CANCER 61 Perifosine 61 Afatinib 61 naïve HCV 61 Accelerated Partial Breast Irradiation 61 MDV# 61 PRN FDA Approves 61 mCRC 61 Perifosine KRX 61 Telaprevir VX 61 Shows Statistically Significant 61 non resectable 61 HCV NS5B polymerase 61 elderly myelodysplastic syndromes 61 Ranolazine 61 lung pancreatic 61 PROSTASCINT R 61 Tipranavir 61 RCW breast cancer 61 Myocet 61 immunotherapeutic vaccine 61 KRAS mutations occur 61 Azedra 61 vandetanib 61 alpha folate receptor 61 Intravitreal 61 oral dual endothelin 61 whose tumors overexpress 61 advanced hepatocellular carcinoma 61 metastatic dermatofibrosarcoma protuberans DFSP 61 doxorubicin HCl liposome injection 61 alkylating agent 61 GVAX ® 61 multicentre randomized 61 Successfully Completes Phase 61 evaluating mipomersen 61 Lymphocytic 61 PREZISTA r 61 Ixabepilone 61 OAB overactive bladder 61 Seliciclib CYC# 61 GATTEX ™ 61 taxane refractory 61 ALN HPN 61 pharmacogenomic translational research 61 herpetic keratitis 61 TNFerade TM 61 ACAPODENE 61 Elvitegravir 61 Pazopanib 61 OncoVex 61 OncoVEX GM CSF 61 FOLFOX chemotherapy 61 ribavirin RBV 61 arsenic trioxide injection 61 Hodgkin lymphoma HL 61 rapid virologic response 61 unstable angina UA 61 Fludara 61 selective androgen receptor modulator 61 Tarvacin Anti Cancer 61 boosted protease inhibitor 61 retinal vein occlusion induced 61 MIVI III 61 brivanib 61 Application BLA 61 pivotal Phase III 61 EGFR HER2 61 tesmilifene 61 Sanofi Aventis Taxotere 61 systemic juvenile idiopathic 61 Soliris eculizumab 61 FOLFIRI alone 61 Protease Inhibitor 61 leading oral taxane 61 Taxotere chemotherapy 61 Tocosol Paclitaxel 61 investigational pharmacologically unique 61 Systemic Sclerosis 61 non alcoholic steatohepatitis 61 pharmacologically active isomer 61 refractory AML 61 Pegylated Interferon 61 Atypical Hemolytic Uremic Syndrome 61 recurrent malignant glioma 61 cyclophosphamide methotrexate 61 rheumatoid arthritis psoriatic arthritis 61 personalized dendritic cell 61 Tramiprosate ALZHEMED TM 61 refractory NSCLC 61 ILUVIEN ® 61 Bendamustine 61 Phase Ib study 61 CVac 61 atrial fibrillation budiodarone ATI 61 kidney urologic 61 lorvotuzumab mertansine 61 BARACLUDE ® 61 docetaxel prednisone 61 sipuleucel T 61 Humanized Anti 61 overactive bladder VANTAS 61 INCB# [003] 61 IMPDH inhibitor 61 Targretin capsules 61 Adjuvant Chemotherapy 61 investigational integrase inhibitor 61 neoadjuvant 61 Phase 2a Trial 61 sodium thiosulfate STS 61 Initiated Phase 61 alefacept 61 DEB# 61 GV# [001] 61 Heterozygous Familial Hypercholesterolemia 61 MGd 61 terlipressin 61 relapsed ALL 61 oral clodronate 61 Epidermal Growth Factor Receptor 61 generation DACH Platinum 61 mildly symptomatic 61 ® bevacizumab 61 Initiate Phase III 61 R vitespen 61 CIMZIA TM certolizumab pegol 61 oral proteasome inhibitor 61 personalized cellular immunotherapy 61 6 sulfatase 61 sodium Injection 61 Neulasta R 61 TYGACIL 61 GlaxoSmithKline Tykerb 61 carcinoma HCC 61 plus Copegus R 61 infliximab monotherapy 61 Anti Tumor Activity 61 Topline Results 61 lintuzumab 61 Iluvien ® 61 Pyridorin 61 ovarian esophageal 61 Zoraxel 61 class anticancer quinolone 61 Relapsed Refractory Multiple Myeloma 61 liver resection surgeries 61 Contrave# 61 Xanafide 61 Mg Uk 61 diagnosed GBM 61 Custirsen 61 Curaxin CBLC# 61 Alkeran 61 immunomodulatory therapy 61 Immunotherapeutic 61 anti EGFR antibody 61 Ophena 61 Pertuzumab 61 reslizumab 61 rALLy clinical trial 61 Paraplatin ® carboplatin 61 Pivotal Clinical Trial 61 miconazole Lauriad